336 related articles for article (PubMed ID: 17121910)
1. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
Ohno H; Kubo K; Murooka H; Kobayashi Y; Nishitoba T; Shibuya M; Yoneda T; Isoe T
Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
[TBL] [Abstract][Full Text] [Related]
2. The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model.
Ohno H; Uemura Y; Murooka H; Takanashi H; Tokieda T; Ohzeki Y; Kubo K; Serizawa I
Eur J Immunol; 2008 Jan; 38(1):283-91. PubMed ID: 18085662
[TBL] [Abstract][Full Text] [Related]
3. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
[TBL] [Abstract][Full Text] [Related]
4. The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis.
Uemura Y; Ohno H; Ohzeki Y; Takanashi H; Murooka H; Kubo K; Serizawa I
J Neuroimmunol; 2008 Mar; 195(1-2):73-80. PubMed ID: 18378004
[TBL] [Abstract][Full Text] [Related]
5. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
Manthey CL; Johnson DL; Illig CR; Tuman RW; Zhou Z; Baker JF; Chaikin MA; Donatelli RR; Franks CF; Zeng L; Crysler C; Chen Y; Yurkow EJ; Boczon L; Meegalla SK; Wilson KJ; Wall MJ; Chen J; Ballentine SK; Ott H; Baumann C; Lawrence D; Tomczuk BE; Molloy CJ
Mol Cancer Ther; 2009 Nov; 8(11):3151-61. PubMed ID: 19887542
[TBL] [Abstract][Full Text] [Related]
6. High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
Fujita H; Gomori A; Fujioka Y; Kataoka Y; Tanaka K; Hashimoto A; Suzuki T; Ito K; Haruma T; Yamamoto-Yokoi H; Harada N; Sakuragi M; Oda N; Matsuo K; Inada M; Yonekura K
PLoS One; 2016; 11(10):e0164830. PubMed ID: 27736957
[TBL] [Abstract][Full Text] [Related]
7. Anti-c-Fms antibody inhibits lipopolysaccharide-induced osteoclastogenesis in vivo.
Kimura K; Kitaura H; Fujii T; Hakami ZW; Takano-Yamamoto T
FEMS Immunol Med Microbiol; 2012 Mar; 64(2):219-27. PubMed ID: 22067001
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals.
Hiraga T; Nakamura H
Int J Cancer; 2009 Jan; 124(1):215-22. PubMed ID: 18814279
[TBL] [Abstract][Full Text] [Related]
9. The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity.
Kim HJ; Yoon HJ; Choi JY; Lee IK; Kim SY
J Leukoc Biol; 2014 Feb; 95(2):337-45. PubMed ID: 24130113
[TBL] [Abstract][Full Text] [Related]
10. M-CSF mediates TNF-induced inflammatory osteolysis.
Kitaura H; Zhou P; Kim HJ; Novack DV; Ross FP; Teitelbaum SL
J Clin Invest; 2005 Dec; 115(12):3418-27. PubMed ID: 16294221
[TBL] [Abstract][Full Text] [Related]
11. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
12. Specific targeting of PKCδ suppresses osteoclast differentiation by accelerating proteolysis of membrane-bound macrophage colony-stimulating factor receptor.
Kim MY; Lee K; Shin HI; Jeong D
Sci Rep; 2019 May; 9(1):7044. PubMed ID: 31065073
[TBL] [Abstract][Full Text] [Related]
13. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
[TBL] [Abstract][Full Text] [Related]
14. Anti-c-fms Antibody Prevents Osteoclast Formation and Bone Resorption in Co-Culture of Osteoblasts and Osteoclast Precursors In Vitro and in Ovariectomized Mice.
Nara Y; Kitaura H; Ogawa S; Shen WR; Qi J; Ohori F; Noguchi T; Marahleh A; Pramusita A; Kinjo R; Mizoguchi I
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854340
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity.
El Hajj Dib I; Gallet M; Mentaverri R; Sévenet N; Brazier M; Kamel S
Eur J Pharmacol; 2006 Dec; 551(1-3):27-33. PubMed ID: 17049513
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292.
Furugaki K; Moriya Y; Iwai T; Yorozu K; Yanagisawa M; Kondoh K; Fujimoto-Ohuchi K; Mori K
Clin Exp Metastasis; 2011 Oct; 28(7):649-59. PubMed ID: 21688034
[TBL] [Abstract][Full Text] [Related]
18. A novel osteoclast precursor cell line, 4B12, recapitulates the features of primary osteoclast differentiation and function: enhanced transfection efficiency before and after differentiation.
Amano S; Sekine K; Bonewald LF; Ohmori Y
J Cell Physiol; 2009 Oct; 221(1):40-53. PubMed ID: 19492422
[TBL] [Abstract][Full Text] [Related]
19. Blocking of the Ubiquitin-Proteasome System Prevents Inflammation-Induced Bone Loss by Accelerating M-CSF Receptor c-Fms Degradation in Osteoclast Differentiation.
Lee K; Kim MY; Ahn H; Kim HS; Shin HI; Jeong D
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28946669
[TBL] [Abstract][Full Text] [Related]
20. Growth/differentiation factor-15 inhibits differentiation into osteoclasts--a novel factor involved in control of osteoclast differentiation.
Vanhara P; Lincová E; Kozubík A; Jurdic P; Soucek K; Smarda J
Differentiation; 2009 Nov; 78(4):213-22. PubMed ID: 19695766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]